Skip to main content

Table 3 Grouping of tumors used for evaluation of ATM's impact on resistance to chemotherapy

From: Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

 

TP53/CHEK2status

 

Wild-type

Mutated

Progressive disease

A

B

Responders

C

D

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us